Pneumocystis jirovecii pneumonia in a patient with Anti-N-Methyl-D-Aspartate receptor postherpetic encephalitis

Pediatric Infectious Disease Journal

Volumn 35, Issue 7, 2016, Pages 816-817

  García Moreno, Jorge ^a   Igartua Laraudogoitia, Jon ^a   Montes Ros, Milagrosa ^a  

^a HOSPITAL DONOSTIA   (Spain)

Author keywords

anti NMDAr encephalitis; children; Pneumocystis jirovecii; pneumonia; rituximab

Indexed keywords

ACICLOVIR; AMIKACIN; AMPHOTERICIN B; C REACTIVE PROTEIN; CEFEPIME; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOBUTAMINE; DOPAMINE; FUNGAL DNA; IMIPENEM; IMMUNOGLOBULIN; METHYLPREDNISOLONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR ANTIBODY; NITRIC OXIDE; OXYGEN; PROCALCITONIN; RITUXIMAB; VANCOMYCIN; BIOLOGICAL PRODUCT; IMMUNOLOGIC FACTOR;

ADD ON THERAPY; ADULT RESPIRATORY DISTRESS SYNDROME; ANTI N METHYL D ASPARTATE RECEPTOR ENCEPHALITIS; ANTIBODY DETECTION; ARTICLE; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CHOREOATHETOSIS; HERPES SIMPLEX ENCEPHALITIS; HUMAN; HYPOKALEMIA; HYPOXEMIA; INFANT; LUMBAR PUNCTURE; LUNG INFILTRATE; LUNG LAVAGE; LYMPHOCYTOPENIA; MALE; NEUROLOGIC EXAMINATION; NONHUMAN; NONINVASIVE VENTILATION; OXYGEN THERAPY; PHYSICAL EXAMINATION; PLEOCYTOSIS; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THORAX RADIOGRAPHY; TREATMENT RESPONSE; VIRUS REACTIVATION; ANTI-N-METHYL-D-ASPARTATE RECEPTOR ENCEPHALITIS; ISOLATION AND PURIFICATION; MICROBIOLOGY; PATHOLOGY; PNEUMOCYSTIS CARINII; PNEUMONIA, PNEUMOCYSTIS; VIROLOGY;

ANTI-N-METHYL-D-ASPARTATE RECEPTOR ENCEPHALITIS; BIOLOGICAL PRODUCTS; HUMANS; IMMUNOLOGIC FACTORS; INFANT; MALE; PNEUMOCYSTIS CARINII; PNEUMONIA, PNEUMOCYSTIS; RITUXIMAB;

EID: 84964334305     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000001165     Document Type: Article

References (9)

1. Granerod J, Ambrose HE, Davies NW, et al.; UK Health Protection Agency (HPA) Aetiology of Encephalitis Study Group. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis. 2010;10:835-844.
2. Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10:63-74.
3. Vargas SL, Hughes WT, Santolaya ME, et al. Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants. Clin Infect Dis. 2001;32:855-861.
4. Cragg MS, Walshe CA, Ivanov AO, et al. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun. 2005;8:140-174.
5. Elsegeiny W, Eddens T, Chen K, et al. Anti-CD20 antibody therapy and susceptibility to Pneumocystis pneumonia. Infect Immun. 2015;83:2043-2052.
6. Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014;83:142-150.
7. Martin-Garrido I, Carmona EM, Specks U, et al. Pneumocystis pneumonia in patients treated with rituximab. Chest. 2013;144:258-265.
8. Chitnis T, Waubant E. B-cell depletion in children with neuroimmunologic conditions: the learning curve. Neurology. 2014;83:111-112.
9. Moon SM, Kim T, Sung H, et al. Outcomes of moderate-To-severe Pneumocystis pneumonia treated with adjunctive steroid in non-HIVinfected patients. Antimicrob Agents Chemother. 2011;55:4613-4618.